Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Alzheimer Disease

Magic mushrooms and Alzheimer’s: what one remarkable case can tell us

Magic mushrooms are better known for producing hallucinations and altering people’s sense of reality than for treating brain diseases. Most people associate them with tripping, rather than Alzheimer’s disease.

The Conversation

A Blood Test That Detects Alzheimer's Disease Years Before Brain Scans Can Just Took a Major Leap Forward — Harvard Study Confirms It Outperforms PET Imaging in Early Detection

Harvard Mass General Brigham study in Nature Communications (April 2026): plasma pTau217 blood test detects Alzheimer's progression years before PET scans. FDA already cleared Lumipulse pTau217 test for symptomatic patients.

Medical Daily

Alzheimer's Treatment Is Entering a New Era — Here Is Everything That Has Changed in 2026

Leqembi and Kisunla are slowing Alzheimer's decline by 27-35% in early-stage patients. The 2026 drug pipeline has 158 candidates in 192 trials. Prevention trials are beginning. Here's the full update.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Glucosamine supplements may speed memory loss from Alzheimer’s, new research shows

People with Alzheimer’s disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn’t. That’s the key finding of a new study that my colleagues and I published in the journal Nature Metabolism.

The Conversation

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

MarketBeat

Air pollution could be affecting your brain power

The impacts are similar to what researchers would expect from 10 years of normal aging

The Independent UK

Blood test could detect Alzheimer's 'decades before'

Using blood tests to pinpoint changes in the brain "could be incredibly valuable" for the early detection of Alzheimer's disease, researchers say.

AAP

Read news from The Economist, FT, and more,
with one subscription

How a simple blood test could spot signs of Alzheimer’s ‘decades before symptoms’

A simple blood test may be able to spot signs of Alzheimer’s disease long before someone shows symptoms, a new study has revealed

The Independent UK

Blood test could detect signs of Alzheimer’s ‘decades before symptoms’ – study

The findings show that Alzheimer’s may be present in midlife and already linked to cognitive differences, researchers said.

Evening Standard

The ‘Sweet’ Habit Researchers Say Could Raise Your Alzheimer’s Risk

Many people think of sugary snacks as harmless comfort foods, especially during stressful days or late-night cravings. However, growing research suggests that regularly consuming large...

Saving Advice

Blood biomarkers could detect earliest signs of Alzheimer’s disease – and slow its progression

Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions worldwide, has a long preclinical stage. It potentially begins decades before clinical symptoms become apparent.

The Conversation

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo

MarketBeat

Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients…

AAP

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clin

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s disease pipeline. On the company’s first-quarter 2026 earnings call, Chief Executive Offic

The Independent UK

Eating eggs five times a week could slash Alzheimer’s risk

While no diet can cure or reverse Alzheimer’s eggs contain nutrients that scientists believe can boost brain health

The Independent UK

Scientists unveil Alzheimer’s finger prick test to predict risk of disease

Researchers found the blood test can be used with computerised cognitive testing to identify a person’s risk of Alzheimer’s

Fit & Well

The mouth-brain link: how healthy gums could help protect against Alzheimer’s disease

Four tips for better oral health—which could mean better brain health too

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

I’m a ‘sandwich-generation’ caregiver. Chances are you will be, too

Some 16 million Americans in mid-life caring for aging relatives and minor children at the same time - and those numbers are expected to grow significantly in the coming decades. America isn’t ready, Julia Musto discovers

The Conversation

The four types of dementia most people don’t know exist

What most people think of when they hear the word “dementia” is memory problems and forgetfulness. But what people often don’t know is that dementia can cause many different symptoms – affecting speech, behaviour, sleep, motor function and more.

The Conversation

Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss

Most people think of Alzheimer’s disease as an illness of aging. But in fact, the brain changes that characterize it begin much earlier – sometime around the third decade of life.

The Independent UK

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost

The Conversation

Hormone therapy and dementia risk: what a new study says about menopause treatment

Hormone therapy is widely used to treat menopausal symptoms such as hot flushes and night sweats. But scientists have long debated whether it affects dementia risk.

Euronews

Reading, puzzles and learning new skills may help delay Alzheimer’s disease, study suggests

Keeping your brain active throughout life by learning new skills or reading could help delay Alzheimer’s disease.

Sports Illustrated

Beyond the Slopes: Mikaela Shiffrin’s Mission to Help Educate Families Facing Early Symptomatic Alzheimer’s Disease

Mikaela was compensated for her time by Eli Lilly and Company. The Most Decorated Skier of Our Time Mikaela Shiffrin knows what it means to chase down a challen

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Alzheimer Research UK

155 stories

Nature Communications

Eli Lilly and Company

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.